Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 235

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 235
---
 applicable independence and other requirements; |

| ● | recommending candidates to serve as nominee for director for the annual meeting of the stockholders; |

| ● | reviewing the performance of the Board and management and making recommendations to the Board for areas for improvement; |

| ● | overseeing the Board committee structure and operations and making recommendations to the Board regarding the membership of the committees of the Board; and |

| ● | developing, reviewing and assessing, and overseeing and monitoring compliance with, our corporate governance guidelines and the Code of Business Conduct and Ethics. |

The members of the nominating and corporate governance committee are Cynthia Smith and Susan Shiff. Cynthia Smith is the chair of the nominating and corporate governance committee. The composition of the nominating and corporate governance committee meets the requirements for independence under, and complies with, any applicable requirements of the rules and regulations of Nasdaq.

138

EXECUTIVE COMPENSATION To achieve our goals, we have designed our compensation and benefits program to attract, retain, incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving these goals. We believe our compensation program should promote the success of the Company and align executive incentives with the long-term interests of our stockholders. As our needs evolve, we intend to continue to evaluate our philosophy and compensation programs as circumstances require. This section provides an overview of our and Legacy Tvardi’s executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. This section also sets forth information relating to the compensation earned by Cara’s named executive officers for the fiscal years ended December 31, 2024 and 2023, as well as certain information regarding equity awards granted to Cara’s named executive officers that remained outstanding as of December 31, 2024. The pre-Merger compensation, including equity awards, disclosed below for Cara’s and Legacy Tvardi’s named executive officers has been adjusted to give retroactive effect to the Reverse Stock Split and Exchange Ratio. Unless otherwise indicated, as used in this section, “Tvardi,” the “Company,” “we,” “us” and “our” refer to Legacy Tvardi prior to the closing of the Merger and Tvardi Therapeutics, Inc. after the closing of the Merger. For the year ended December 31, 2024, Legacy Tvardi’s named executive officers were:

| ● | Imran Alibhai, Ph.D., Chief Executive Officer and Director; |